Antonia Martinetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonia Martinetti has a total of 484 co-authors. Here are the top co-authors by number of shared publications:
- Filippo Pietrantonio
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
45 shared publications - Ettore Seregni
Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
38 shared publications - Chiara Cremolini
Department of Oncology, University Hospital of Pisa, Pisa, Italy
35 shared publications - Sara Lonardi
Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
33 shared publications - Francesca Corti
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
32 shared publications - Antoine Cazelles
Department of Digestive and Oncological Surgery, Hôpital Européen Georges Pompidou , 20 rue Leblanc, 75015 Paris
31 shared publications
Latest Publications
- 28 November 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2470-2477
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study
- 28 November 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2470-2477
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Heatmap with unsupervised clustering in the validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Heatmap with unsupervised clustering in the validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Survival after recurrence in MSI patients from PETACC8 trial with available 3’RNAseq data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Survival after recurrence in MSI patients from PETACC8 trial with available 3’RNAseq data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Selection of the transcriptomic signatures for the unsupervised clustering
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Selection of the transcriptomic signatures for the unsupervised clustering
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the unsupervised clusters and the line of immune checkpoint inhibitor
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the unsupervised clusters and the line of immune checkpoint inhibitor
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the three unsupervised clusters in the validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the three unsupervised clusters in the validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Tumor mutational burden and diagnosed Lynch syndrome in patients with MSI-high status determined by only one method
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Tumor mutational burden and diagnosed Lynch syndrome in patients with MSI-high status determined by only one method
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Selection of the transcriptomic signatures for the unsupervised clustering
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Selection of the transcriptomic signatures for the unsupervised clustering
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the three unsupervised clusters in the validation cohort
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Kaplan Meier curves for progression-free survival according to the three unsupervised clusters in the validation cohort
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Heatmap with unsupervised clustering in the validation cohort
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Heatmap with unsupervised clustering in the validation cohort